94 related articles for article (PubMed ID: 10675753)
41. Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma.
Harashima A; Matsuo Y; Nishizaki C; Kozuka T; Fukuda S; Sezaki T; Orita K
Hum Cell; 2000 Mar; 13(1):43-54. PubMed ID: 10937346
[TBL] [Abstract][Full Text] [Related]
42. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
[TBL] [Abstract][Full Text] [Related]
44. Characterization of a lineage-negative stem-progenitor cell population optimized for ex vivo expansion and enriched for LTC-IC.
Forraz N; Pettengell R; McGuckin CP
Stem Cells; 2004; 22(1):100-8. PubMed ID: 14688396
[TBL] [Abstract][Full Text] [Related]
45. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis.
Papadaki HA; Tsagournisakis M; Mastorodemos V; Pontikoglou C; Damianaki A; Pyrovolaki K; Stamatopoulos K; Fassas A; Plaitakis A; Eliopoulos GD
Bone Marrow Transplant; 2005 Dec; 36(12):1053-63. PubMed ID: 16205726
[TBL] [Abstract][Full Text] [Related]
46. A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisińska B; Roliński J; Piersiak T; Kandefer-Szerszeń M
Folia Histochem Cytobiol; 2009; 47(1):69-74. PubMed ID: 19419941
[TBL] [Abstract][Full Text] [Related]
47. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
[TBL] [Abstract][Full Text] [Related]
48. Enrichment of residual tumor cells in bone marrow or peripheral blood cells in a neuroectodermal tumor model.
Kremens B; Wieland R; Reuss R; Lennartz K; Havers W
Pediatr Hematol Oncol; 1994; 11(6):625-31. PubMed ID: 7857785
[TBL] [Abstract][Full Text] [Related]
49. Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells.
Zheng X; Abroun S; Otsuyama K; Asaoku H; Kawano MM
Haematologica; 2006 Jul; 91(7):920-8. PubMed ID: 16818279
[TBL] [Abstract][Full Text] [Related]
50. CD52 is not a promising immunotherapy target for most patients with multiple myeloma.
Westermann J; Maschmeyer G; van Lessen A; Dörken B; Pezzutto A
Int J Hematol; 2005 Oct; 82(3):248-50. PubMed ID: 16207599
[TBL] [Abstract][Full Text] [Related]
51. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
Tousková M; Maisnar V; Krejsek J; Kopecký O
Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
[TBL] [Abstract][Full Text] [Related]
52. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
53. Patient-specific 3D microfluidic tissue model for multiple myeloma.
Zhang W; Lee WY; Siegel DS; Tolias P; Zilberberg J
Tissue Eng Part C Methods; 2014 Aug; 20(8):663-70. PubMed ID: 24294886
[TBL] [Abstract][Full Text] [Related]
54. Combined immunomagnetic cell sorting and ELISPOT assay for the phenotypic characterization of specific antibody-forming cells.
Lakew M; Nordström I; Czerkinsky C; Quiding-Järbrink M
J Immunol Methods; 1997 Apr; 203(2):193-8. PubMed ID: 9149813
[TBL] [Abstract][Full Text] [Related]
55. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
[TBL] [Abstract][Full Text] [Related]
56. Reverse Transcriptase-PCR Analysis of Gene Expression in Hematopoietic Stem Cells.
Orlic D
Methods Mol Med; 2002; 63():287-99. PubMed ID: 21437815
[TBL] [Abstract][Full Text] [Related]
57. Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule.
Gindraux F; Selmani Z; Obert L; Davani S; Tiberghien P; Hervé P; Deschaseaux F
Cell Tissue Res; 2007 Mar; 327(3):471-83. PubMed ID: 17109120
[TBL] [Abstract][Full Text] [Related]
58. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
59. [The clonal origin of multiple myeloma].
Wang Y; Wu S; Xue H
Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):663-5. PubMed ID: 8731825
[TBL] [Abstract][Full Text] [Related]
60. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.
Rawstron AC; Barrans SL; Blythe D; English A; Richards SJ; Fenton JA; Davies FE; Child JA; Jack AS; Morgan GJ
Br J Haematol; 2001 Jun; 113(3):794-802. PubMed ID: 11380472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
